Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440937 | 0.87 | APP (0.56) | HRH3APPSENP8SENP7SENP6 | |
| SCHEMBL9946093 | 0.83 | ENPP2 (0.58) | MAOBFFAR1 | |
| SCHEMBL9946078 | 0.82 | MAOB (0.56) | HRH3APPSENP8SENP7SENP6 | |
| SCHEMBL16440936 | 0.82 | FFAR1 (0.54) | HRH3APPSENP8SENP7SENP6 | |
| SCHEMBL16428800 | 0.82 | FFAR1 (0.54) | HRH3APPSENP8SENP7SENP6 | |
| SCHEMBL9946049 | 0.81 | MAOB (0.61) | APPSENP8SENP7SENP6MAOB | |
| SCHEMBL13845303 | 0.80 | APP (0.61) | HRH3APPSENP8SENP7SENP6 | |
| SCHEMBL10784840 | 0.80 | LTA4H (0.64) | HRH3MAOBBCHEFFAR1LTA4H | |
| SCHEMBL9946052 | 0.80 | LMNA (0.60) | MAOBBCHE | |
| SCHEMBL19864469 | 0.80 | MAOB (0.57) | HRH3APPSENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LPL 2017/4885LIPG 1774/4885HRH3 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.